GLYTHERA LIMITED United Kingdom

Glythera is an early-stage Biotechnology company focused on the development of next-generation biologics, principally Antibody Drug Conjugates (ADCs) for cancer indications.

The Company’s ADC pipeline is based on an industry-leading, proprietary conjugation platform, ‘PermaLink’, which enables ADCs with higher therapeutic indices – a clear market need in fighting difficult-to-treat tumours. PermaLink is a cysteine-specific, non-maleimide approach that demonstrates significantly improved ADC conjugation stability and improved product homogeneity resulting in improved TI and patient safety profiles. Through PermaLink, Glythera is able to combine novel, highly potent toxins that induce apoptosis with novel antibodies that target cancer-specific antigens, especially those that are highly overexpressed in solid tumours.

The company is currently using its proprietary technology and access to a broad range of toxin payloads to develop a portfolio of class leading ADCs. Glythera is funded by IP Group and the North East Technology Fund and is based in Newcastle Upon Tyne, England.

Website:
glythera.com
Organisation type
Dr David Simpson
CEO 
Dr Ian Evetts
Chief Business Officer